Zobrazeno 1 - 10
of 37
pro vyhledávání: '"M J, Goudier"'
Autor:
E. Vuillemin, B. Lucas, Frank Priou, Pierre Kerbrat, Hélène Simon, Gérard Ganem, R. Delva, Christian Riche, Alain Lortholary, Erick Gamelin, Hugues Bourgeois, M.-J. Goudier, A-C. Hardy-Bessard, F. Grude, S. Van Hulst, Patrick Soulié, Mario Campone
Publikováno v:
Oncologie. 12:362-368
L’Observatoire des medicaments et des innovations therapeutiques (OMIT) Bretagne et Pays de la Loire a ete cree en 2003 par lesAgences regionales de l’hospitalisation (ARH) respectives. Il est specialise en cancerologie, assure le suivi qualitati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::02143a1e45163fa187b8ab961207b5b2
https://doi.org/10.1007/s10269-010-1888-5
https://doi.org/10.1007/s10269-010-1888-5
Autor:
Pierre Fargeot, Bruno Audhuy, A Monnier, Jean-Paul Guastalla, P. Kerbrat, Philippe Montcuquet, P. Fumoleau, S Walter, Alain Lortholary, Ph. Chollet, H Simon, Henri Roché, C Veyret, Moïse Namer, Pierre Clavere, M.-J. Goudier, Jacques Bonneterre, J.-C. Eymard
Publikováno v:
British Journal of Cancer
The aim of the study was to compare our reference adjuvant chemotherapy, FEC100 (fluorouracil 500 mg m(-2), epirubicin 100 mg m(-2) and cyclophosphamide 500 mg m(-2), six cycles every 21 days), to an epirubicin-vinorelbine (Epi-Vnr) combination for e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8603a26af3eaea0cf7f0237a10e6f70f
http://europepmc.org/articles/PMC2359910
http://europepmc.org/articles/PMC2359910
Autor:
Pierre Clavere, Jean-Paul Guastalla, P. Fargeot, P. Fumoleau, A. Monnier, D. Serin, P. Kerbrat, M.-J. Goudier, Ph. Chollet, Jacques Bonneterre, Henri Roché
Publikováno v:
Annals of Oncology. 17:1221-1227
Background: The purpose of this study was to determine optimal adjuvant therapy between complete hormonal blockade in premenopausal patients with hormone receptor positive breast cancer and one to three positive nodes. Patients and methods: We random
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8983b53e16dc67a3b2dd36c07e42206
https://doi.org/10.1093/annonc/mdl107
https://doi.org/10.1093/annonc/mdl107
Autor:
P. Fumoleau, M.-J. Goudier, Philippe Montcuquet, Henri Roché, P. Kerbrat, Pascale Romestaing, Elisabeth Luporsi, Moïse Namer, P. Fargeot, Jacques Bonneterre, A. Monnier
Publikováno v:
Annals of Oncology. 17:85-92
The aim of the study was to evaluate and compare incidence and risk factors of left ventricular dysfunction (LVD) in early breast cancer patients receiving (E+) or not (E-) epirubicin-based adjuvant chemotherapy.Among eight FASG trials, 3577 assessab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee9e035c1aaee28bdac335ad7eeaa5c5
https://doi.org/10.1093/annonc/mdj034
https://doi.org/10.1093/annonc/mdj034
Autor:
Erick C. Gamelin, Paul H. Gesta, M. J. Goudier, Philippe J. Maillart, Etienne M. Danquechin-Dorval, Yvan F. Dumesnil, Pascal C. Burtin, Alain H. Lortholary, Remy G. Delva, Francis G. Larra
Publikováno v:
Cancer. 77:441-451
BACKGROUND A phase II prospective trial was carried out to study the concept of 5-fluorouracil (5-FU) dose-intensity in patients with advanced colorectal cancer. Forty patients were treated with 5-FU plus leucovorin (LV), with individually increasing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::21c9fc7f6e90ed8824c585b77e2d3187
https://doi.org/10.1002/(sici)1097-0142(19960201)77:3<441::aid-cncr4>3.0.co
https://doi.org/10.1002/(sici)1097-0142(19960201)77:3<441::aid-cncr4>3.0.co
Autor:
M. Héry, E. Cabarrot, D. Gedouin, F. Plat, A. Monnier, Moïse Namer, J. Ph. Jacquin, J. P. Gérard, M. J. Goudier, P. Hurteloup, Daniel Serin, P. Fumoleau
Publikováno v:
Drugs. 45:60-67
In 1986 the true benefit of adjuvant medical treatment in postmenopausal patients with pathological node-positive breast adenocarcinoma was still controversial. The French Adjuvant Study Group (FASG) initiated a randomised trial to elucidate the resp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3c0ba62ff501c0b14fe33b6fdfc9abeb
https://doi.org/10.2165/00003495-199300452-00010
https://doi.org/10.2165/00003495-199300452-00010
Autor:
Pascale Romestaing, M.-J. Goudier, P. Fargeot, Henri Roché, M. Campone, A. Monnier, Jacques Bonneterre, P. Kerbrat, Moïse Namer, P. Fumoleau, Philippe Montcuquet
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 16(8)
Background: The purpose of this study was to evaluate incidence and risk factors of secondary leukemia after adjuvant epirubicin-based chemotherapy in breast cancer patients. Patients and methods: Among eight French Adjuvant Study Group trials, 3653
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96a61ffa172a6e36e82a5e25ec8e0ed5
https://pubmed.ncbi.nlm.nih.gov/15905306
https://pubmed.ncbi.nlm.nih.gov/15905306
Autor:
Laurent Zelek, W. Sutherland, F. L. Turpin, Ph. Chollet, M. J. Goudier, Y. Brewer, D. Martin, P. Fumoleau, J-Y Pierga, J. L. Baticle, Moïse Namer, J. C. Barats, M. Gil-delgado
Publikováno v:
Breast cancer research and treatment. 88(2)
Background. A retrospective source review identifying predictive factors and assessing safety and efficacy in pretreated metastatic breast cancer (MBC) patients treated with capecitabine in a French compassionate-use program. Patients and methods. 19
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e464580f703d2317e122ec1d842cfcce
https://pubmed.ncbi.nlm.nih.gov/15564795
https://pubmed.ncbi.nlm.nih.gov/15564795
Autor:
S Gauthier, M. Benmiloud, G. Netter-Pinon, T. Facchini, C. Gousset, D. Belpomme, F. N. Marié, M.-J. Goudier, M. Frenay, I Krakowski, Franck Sturtz, E. Pujade-Lauraine
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 11(11)
Summary Background Verapamil (VER), a potent calcium channel blocker, has been found to overcome P-gp-mediated multidrug resistance (MDR) and to increase sensitivity to cytotoxic anticancer drugs in refractory myeloma and non-Hodgkin lymphorna. The v
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76b6885b89a80411ee74677128333d20
https://pubmed.ncbi.nlm.nih.gov/11142488
https://pubmed.ncbi.nlm.nih.gov/11142488
Autor:
A. Cattan, M. Mousseau, P. Herait, Ch. Chevreau, Pierre Kerbrat, P. Lucas, A. Monnier, B. Chevallier, M. J. Goudier, B. Coiffier, Ph. Bastit, Marc Spielmann, Pierre Fumoleau, T. Delozier, H. Roche, Moïse Namer
Publikováno v:
European Journal of Cancer and Clinical Oncology. 26:821-823
79 patients with advanced breast cancer were given Pirarubicin 20-25 mg/m2 during 3 consecutive days every 3 or 4 weeks. 78 were evaluable for response (41 without previous chemotherapy and 37 with only one previous regimen). The overall response rat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a41ba83dae7b27d6de5f5f966b43c45
https://doi.org/10.1016/0277-5379(90)90161-l
https://doi.org/10.1016/0277-5379(90)90161-l